Meanwhile, the BOOSTER trial and WJOG8715L trial studied the efficacy of this combination for patients with confirmed EGFR‐T790M mutant NSCLC as second‐line treatment. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.